LYEL · Insider Trading
Lyell Immunopharma, Inc. Common Stock
Every open-market purchase and sale reported by LYEL officers, directors and 10%+ beneficial owners on SEC Form 4, which must be filed within two business days of the transaction. Sales often reflect scheduled 10b5-1 plans or tax withholding rather than a directional view, so read counts alongside the size and the filer.
| Filed | Insider | Role | Type | Shares | Value |
|---|---|---|---|---|---|
| 2026-09-10 | David Shook | Chief Medical Officer | Sell | −500 | −$6.35K |
| 2026-09-10 | Jarrad Mattieu Aguirre | Chief Medical Officer | A | — | — |
| 2026-08-25 | Gary K. Lee | Chief Scientific Officer | Sell | −1,457 | −$22.64K |
| 2026-08-25 | Stephen J. Hill | Chief Operating Officer | Sell | −989 | −$15.37K |
| 2026-08-25 | Lynn Seely | President and CEO | Sell | −9,589 | −$149.01K |
| 2026-08-11 | Veronica Sanchez Bulis | VP, Corporate Controller | Sell | −621 | −$8.91K |
| 2026-08-11 | Lynn Seely | President and CEO | Sell | −390 | −$5.59K |
| 2026-08-11 | Gary K. Lee | Chief Scientific Officer | Sell | −131 | −$1.88K |
| 2026-08-11 | Stephen J. Hill | Chief Operating Officer | Sell | −89 | −$1.28K |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | J | −38,500 | — |
| 2026-07-27 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | J | −44,000 | — |
| 2026-07-20 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | Sell | −10 | −$137 |
| 2026-07-17 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | Sell | −10 | −$137 |
| 2026-07-01 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | J | −76,000 | — |
| 2026-06-18 | Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | J | −66,500 | — |
| 2026-06-15 | Lynn Seely | President and CEO | Sell | −388 | −$7.34K |
| 2026-06-15 | Stephen J. Hill | Chief Operating Officer | Sell | −89 | −$1.68K |
| 2026-06-15 | Veronica Sanchez Bulis | VP, Corporate Controller | Sell | −217 | −$4.10K |
| 2026-06-15 | Gary K. Lee | Chief Scientific Officer | Sell | −130 | −$2.46K |
| 2026-06-12 | Mark Bachleda | Director | A | +9,250 deriv. | — |
| 2026-06-12 | Richard Klausner | Director | A | — | — |
| 2026-06-12 | Otis W Brawley | Director | A | — | — |
| 2026-06-12 | Elizabeth G Nabel | Director | A | +9,250 deriv. | — |
| 2026-06-12 | Cathy Friedman | Director | A | — | — |
| 2026-06-12 | William Jl Rieflin | Director | A | +9,250 deriv. | — |
| 2026-06-12 | Sumant Ramachandra | Director | A | — | — |
| 2026-06-11 | David Shook | Chief Medical Officer | Sell | −1,977 | −$24.99K |
| 2026-03-16 | Smital Shah | Chief Fin. and Bus. Officer | A | +140,000 deriv. | — |
| 2026-03-09 | Paul L Berns | 10%+ Owner | Buy | +4,392,810 | +$112.50M |
| 2026-03-09 | ARCH Venture Partners IX, LLC | 10%+ Owner | Buy | +2,440,450 | +$62.50M |
| 2026-02-12 | Gary K. Lee | Chief Scientific Officer | Sell | −1,671 | −$39.08K |
| 2026-02-12 | Stephen J. Hill | Chief Operating Officer | Sell | −1,236 | −$28.91K |
| 2026-02-12 | Lynn Seely | President and CEO | Sell | −7,455 | −$174.37K |
| 2026-02-11 | Mark A Meltz | General Counsel | A | +50,000 deriv. | — |
| 2026-02-11 | Veronica Sanchez Bulis | VP, Corporate Controller | MIXED | +8,496 | −$5.87K |
| 2026-02-11 | Lynn Seely | President and CEO | MIXED | +19,562 | −$10.13K |
| 2026-02-11 | Stephen J. Hill | Chief Operating Officer | MIXED | +3,891 | −$2.52K |
| 2026-02-11 | Gary K. Lee | Chief Scientific Officer | MIXED | +3,853 | −$3.40K |
| 2026-02-11 | David Shook | Chief Medical Officer | A | — | — |
| 2026-01-06 | Veronica Sanchez Bulis | VP, Corporate Controller | Sell | −2,072 | −$74.18K |
| 2025-11-12 | Stephen J. Hill | Chief Operating Officer | Sell | −95 | −$1.53K |
| 2025-11-12 | Veronica Sanchez Bulis | VP, Corporate Controller | Sell | −239 | −$3.85K |
| 2025-11-12 | Lynn Seely | President and CEO | Sell | −412 | −$6.64K |
| 2025-11-12 | Gary K. Lee | Chief Scientific Officer | Sell | −138 | −$2.23K |
| 2025-10-29 | Lynn Seely | President and CEO | A | — | — |
| 2025-10-29 | Gary K. Lee | Chief Scientific Officer | A | — | — |
| 2025-10-29 | Stephen J. Hill | Chief Operating Officer | A | — | — |
| 2025-08-22 | Charles W. Newton | Chief Financial Officer | MIXED | +6,547 | −$15.32K |
| 2025-08-22 | Lynn Seely | President and CEO | MIXED | +32,743 | −$76.52K |
| 2025-08-22 | Gary K. Lee | Chief Scientific Officer | MIXED | +6,547 | −$15.32K |
| Insider | Role | Shares Held | Value |
|---|---|---|---|
| Innovative Cellular Therapeutics Holdings Ltd | 10%+ Owner | 2,774,980 | $25.70M |
| Paul L Berns | 10%+ Owner | 910,317 | $8.43M |
| Keith Crandell | 10%+ Owner | 910,317 | $8.43M |
| ARCH Venture Partners IX, LLC | 10%+ Owner | 910,317 | $8.43M |
| Richard Klausner | Director | 190,557 | $1.76M |
| Lynn Seely | President and CEO | 63,899 | $591.70K |
| Charles W. Newton | Chief Financial Officer | 25,306 | $234.33K |
| David Shook | Chief Medical Officer | 20,423 | $189.12K |
| Jarrad Mattieu Aguirre | Chief Medical Officer | 20,279 | $187.78K |
| Stephen J. Hill | Chief Operating Officer | 16,816 | $155.72K |
| Gary K. Lee | Chief Scientific Officer | 16,220 | $150.20K |
| Veronica Sanchez Bulis | VP, Corporate Controller | 14,799 | $137.04K |
| Sumant Ramachandra | Director | 10,000 | $92.60K |
| Matthew Lang | Chief Business Officer | 8,125 | $75.24K |
| Cathy Friedman | Director | 5,000 | $46.30K |
| Otis W Brawley | Director | 1,782 | $16.50K |
Form 4 reports a change in beneficial ownership by an officer, director or 10%+ holder, and must be filed within two business days of the transaction — so this is close to real time, unlike the 45-day-lagged 13F institutional data.
Transaction codes matter more than the raw buy/sell count. Code P is an open-market purchase — an insider choosing to buy with their own money, which is the signal most research treats as informative. Code S is a sale, but sales are frequently pre-scheduled under a 10b5-1 plan or cover tax withholding on vesting equity, so a run of sales often says nothing directional. Codes A and M are grants and option exercises rather than open-market decisions.
Full filing history and per-insider positions are on the LYEL quote page; the site-wide leaderboard is on the insider transactions hub.
Market data may be delayed, incomplete, or inaccurate. Not a recommendation to buy, sell, or hold any security. Verify quotes with your broker before trading. See Terms §17.